Eli Lilly (NYSE:LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on Tuesday. Omvoh is now indicated for both forms of inflammatory bowel ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...